Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34


Cancer statistics, 2010.

Jemal A, Siegel R, Xu J, Ward E.

CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.


Differences in tumor type in low-stage versus high-stage ovarian carcinomas.

Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC.

Int J Gynecol Pathol. 2010 May;29(3):203-11. doi: 10.1097/PGP.0b013e3181c042b6.


Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD.

J Pathol. 2010 May;221(1):49-56. doi: 10.1002/path.2696.


SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors.

Goya R, Sun MG, Morin RD, Leung G, Ha G, Wiegand KC, Senz J, Crisan A, Marra MA, Hirst M, Huntsman D, Murphy KP, Aparicio S, Shah SP.

Bioinformatics. 2010 Mar 15;26(6):730-6. doi: 10.1093/bioinformatics/btq040. Epub 2010 Feb 3.


Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Gilks CB.

J Oncol. 2010;2010:740968. doi: 10.1155/2010/740968. Epub 2009 Dec 30.


Mutation of FOXL2 in granulosa-cell tumors of the ovary.

Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG.

N Engl J Med. 2009 Jun 25;360(26):2719-29. doi: 10.1056/NEJMoa0902542. Epub 2009 Jun 10.


Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.

Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IeM.

Am J Pathol. 2009 May;174(5):1597-601. doi: 10.2353/ajpath.2009.081000. Epub 2009 Apr 6.


The SWI/SNF complex and cancer.

Reisman D, Glaros S, Thompson EA.

Oncogene. 2009 Apr 9;28(14):1653-68. doi: 10.1038/onc.2009.4. Epub 2009 Feb 23. Review.


Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.

PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.


A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.

Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB.

Am J Surg Pathol. 2009 Jan;33(1):14-21. doi: 10.1097/PAS.0b013e3181788546.


ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a.

Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z.

Proc Natl Acad Sci U S A. 2008 May 6;105(18):6656-61. doi: 10.1073/pnas.0801802105. Epub 2008 Apr 30.


Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.

Itamochi H, Kigawa J, Terakawa N.

Cancer Sci. 2008 Apr;99(4):653-8. doi: 10.1111/j.1349-7006.2008.00747.x. Review.


Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.

BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.


Genomic and functional evidence for an ARID1A tumor suppressor role.

Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S.

Genes Chromosomes Cancer. 2007 Aug;46(8):745-50.


The nonsense-mediated decay RNA surveillance pathway.

Chang YF, Imam JS, Wilkinson MF.

Annu Rev Biochem. 2007;76:51-74. Review.


Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.

Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM.

Gynecol Oncol. 2007 May;105(2):404-8. Epub 2007 Feb 9.


Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis.

Viganó P, Somigliana E, Chiodo I, Abbiati A, Vercellini P.

Hum Reprod Update. 2006 Jan-Feb;12(1):77-89. Epub 2005 Sep 19. Review.


Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T.

Nat Med. 2005 Jan;11(1):63-70. Epub 2004 Dec 26.


Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors.

Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB, Moran E.

Int J Cancer. 2004 Nov 20;112(4):636.


Endometriosis and ovarian cancer: thoughts on shared pathophysiology.

Ness RB.

Am J Obstet Gynecol. 2003 Jul;189(1):280-94. Review.


Supplemental Content

Support Center